Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma.

Mediators Inflamm · 2015 · PMC4386709 · PMID 25878402

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

When compared to placebo in patients with poorly controlled eosinophilic asthma, reslizumab has been recently shown to significantly decrease sputum eosinophils and improve lung function, as well as to induce a positive trend towards better asthma control [ 51 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.